AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has

Feel30 Launches Austin-Based Telehealth Platform for Evidence-Proven TRT & Integrated At-Home Phlebotomy Services

2025/12/19 22:45
3 min read

AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has introduced a care model designed to improve access to clinically supervised treatment. Based in Austin, the service provides evidence-based TRT, enclomiphene treatment, and erectile dysfunction medications prescribed by licensed U.S. clinicians, with medications fulfilled through licensed U.S. pharmacies.

Feel30 launches national telehealth TRT with at-home nurse blood draws.

Feel30 was founded on 22nd February 2025, by entrepreneur Thomas Phillips, who sought to address common problems in traditional hormone care, including long wait times, multiple in-person lab visits, slow or delayed pharmacy compounding, confusing pricing with hidden fees, and rigid schedules. 

Internal data from Feel30’s early patient population shows that 40% of men seek evaluation primarily due to sustained low energy compared to earlier stages of life, while 30% enroll after relocating to a new state and needing continuity of TRT care.

Service features include transparent all-inclusive pricing, quarterly at-home nurse blood draws, home or in-clinic lab flexibility, unlimited clinician consultations, discreet pharmacy fulfillment, and scheduling on patients’ terms.

The initial laboratory panel costs $99 to $129 and includes the lab test, the at-home nurse visit or in-clinic option, the medical intake, and the clinician review. Ongoing treatment starts at $199 to $235 per month and includes medication, quarterly at-home nurse blood draws, unlimited clinician consultations, follow-up care, medication management, and discreet shipping. There are no upsells or hidden fees.

The care process begins with a comprehensive blood panel to evaluate testosterone levels and related biomarkers. Patients can receive at-home nurse visits as early as the next day, with optional in-clinic laboratory testing available. Feel30’s licensed clinicians review results and issue prescriptions only when medically appropriate and aligned with established guidelines. Most patients complete their initial evaluation within 48 to 72 hours.

Feel30 is one of the only national TRT providers offering quarterly at-home phlebotomy included in the base membership price, positioning it as a leading option for men seeking convenient, medically supervised hormone therapy.

According to established Endocrine Society guidelines, testosterone therapy should only be prescribed after laboratory testing confirms low testosterone. Testosterone levels naturally decline with age, and clinically low levels may be associated with symptoms like fatigue, reduced libido, decreased muscle mass, increased body fat, and lower motivation. Enclomiphene may be used to increase endogenous testosterone production while preserving fertility.

“Many men experience delays in hormone evaluation because of limited appointment availability or the inconvenience of accessing laboratory services,” said Anneliese Cadena, AGNP-C, board-certified Nurse Practitioner and consultant for Feel30. “Telehealth combined with at-home diagnostics allows timely evaluation and guideline-based prescribing with ongoing medical oversight.”
Telehealth continues to increase in men’s hormone care as patients seek faster evaluation and more flexible access to licensed clinicians. Integrated care models allow clinicians to assess laboratory data remotely, prescribe treatment, and follow up with patients.

Media Contact: Thomas Phillips, support@feel30.com, 833-545-1589

**About Feel30** Feel30 is based in Austin, Texas. The platform provides evidence-based testosterone therapy, enclomiphene treatment, and men’s health services with all-inclusive pricing, at-home lab testing with nurse visits, unlimited clinician support, and fast U.S. pharmacy fulfillment. The company’s mission is to make evidence-based hormone care clearer, faster, and more accessible for busy men nationwide who refuse to wait.

Cision View original content:https://www.prnewswire.com/news-releases/feel30-launches-austin-based-telehealth-platform-for-evidence-proven-trt–integrated-at-home-phlebotomy-services-302646836.html

SOURCE Feel30

Market Opportunity
TRUST AI Logo
TRUST AI Price(TRT)
$0.1392
$0.1392$0.1392
+0.28%
USD
TRUST AI (TRT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Fed rate decision September 2025

Fed rate decision September 2025

The post Fed rate decision September 2025 appeared on BitcoinEthereumNews.com. WASHINGTON – The Federal Reserve on Wednesday approved a widely anticipated rate cut and signaled that two more are on the way before the end of the year as concerns intensified over the U.S. labor market. In an 11-to-1 vote signaling less dissent than Wall Street had anticipated, the Federal Open Market Committee lowered its benchmark overnight lending rate by a quarter percentage point. The decision puts the overnight funds rate in a range between 4.00%-4.25%. Newly-installed Governor Stephen Miran was the only policymaker voting against the quarter-point move, instead advocating for a half-point cut. Governors Michelle Bowman and Christopher Waller, looked at for possible additional dissents, both voted for the 25-basis point reduction. All were appointed by President Donald Trump, who has badgered the Fed all summer to cut not merely in its traditional quarter-point moves but to lower the fed funds rate quickly and aggressively. In the post-meeting statement, the committee again characterized economic activity as having “moderated” but added language saying that “job gains have slowed” and noted that inflation “has moved up and remains somewhat elevated.” Lower job growth and higher inflation are in conflict with the Fed’s twin goals of stable prices and full employment.  “Uncertainty about the economic outlook remains elevated” the Fed statement said. “The Committee is attentive to the risks to both sides of its dual mandate and judges that downside risks to employment have risen.” Markets showed mixed reaction to the developments, with the Dow Jones Industrial Average up more than 300 points but the S&P 500 and Nasdaq Composite posting losses. Treasury yields were modestly lower. At his post-meeting news conference, Fed Chair Jerome Powell echoed the concerns about the labor market. “The marked slowing in both the supply of and demand for workers is unusual in this less dynamic…
Share
BitcoinEthereumNews2025/09/18 02:44
Glenn Hughes Scores His Greatest Chart Debut On His Own

Glenn Hughes Scores His Greatest Chart Debut On His Own

The post Glenn Hughes Scores His Greatest Chart Debut On His Own appeared on BitcoinEthereumNews.com. Nearly 10 years after Resonate, Glenn Hughes scores a new career high as Chosen opens at No. 4 on the Official Rock and Metal Albums chart. NEW YORK, NEW YORK – APRIL 08: Glenn Hughes of Deep Purple speaks onstage during the 31st Annual Rock And Roll Hall Of Fame Induction Ceremony at Barclays Center on April 8, 2016 in New York City. (Photo by Mike Coppola/Getty Images) Getty Images Almost a decade after his last solo album Resonate arrived, Glenn Hughes returns with Chosen. The rock superstar’s fifteenth project under his own name debuts on multiple charts in the United Kingdom, where he remains a legend in his chosen field. Chosen opens inside loftiest tiers on multiple tallies and even gives Hughes his first solo win on one roster. Glenn Hughes Scores First Hit on One Chart Chosen debuts on the Official Albums Downloads chart at No. 60. Hughes scores his first solo win on the list of the bestselling full-lengths and EPs on download platforms like iTunes and Amazon in the U.K., as his latest project arrives. Glenn Hughes Reaches a New Peak Chosen earns its loftiest starting point on the Official Rock and Metal Albums chart, where it kicks off at No. 4. Hughes reaches a new all-time high as the set arrives and collects his second top 10. Resonate peaked at No. 6, earning Hughes his first top 10 bestseller almost 10 years back, while Music for the Divine only spent one frame at No. 33 nearly 20 years ago. Glenn Hughes on the Albums Charts Chosen also brings Hughes to new all-time peak positions on both the Official Albums Sales and Official Physical Albums charts. The set debuts at Nos. 25 and 26 on those tallies, respectively. Only Resonate had previously landed on those lists,…
Share
BitcoinEthereumNews2025/09/18 02:41
Trump is 'seen very little' and could be 'sicker than he let's on': ex-White House insider

Trump is 'seen very little' and could be 'sicker than he let's on': ex-White House insider

An analyst Friday pointed out that President Donald Trump has made fewer public appearances over the past several weeks as questions over his health have continued
Share
Rawstory2026/02/14 00:39